Gilead Presents Four-Year Data of Biktarvy for HIV-1 in Treatment-Naïve Adults at CROI 2021

 Gilead Presents Four-Year Data of Biktarvy for HIV-1 in Treatment-Naïve Adults at CROI 2021

Gilead Presents Four-Year Data of Biktarvy for HIV-1 in Treatment-Naïve Adults at CROI 2021

Shots:

  • The two OLE P-III 1489 and 1490 studies assessing Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) vs dolutegravir-containing triple for the treatment of HIV-1 in treatment naïve adults
  • The study demonstrated the sustained efficacy & safety profile with no treatment-emergent resistance @144wks, >98% of treatment-naïve patients achieved and maintained undetectable viral load @4yrs.; viral suppression in 48wks. OLE period
  • In a subgroup analysis of patients with TDR, Biktarvy achieved comparably high levels of durable viral suppression @144 weeks among participants with and without TDR (98% vs 97%; as treated analysis)

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Devex

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post